How Tech Hubs Can Get Involved at RESI Boston, June 5-7

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

RESI Boston, June 5-7 will be in-person on June 5, followed by two days of virtual partnering on June 6-7. If you are part of a tech hub, Life Science Nation (LSN)’s Redefining Early Stage Investment (RESI) conference series is a great place for companies in the earliest stages of the life science industry to connect with potential investors. An integral part of RESI is the global tech hub ecosystem of accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations.

Through RESI, tech hub affiliated startups gain access to resources beyond partnering with investors and strategic partners. Resources such as the LSN Investor Database, Innovator’s Pitch Challenge (IPC), free workshops, and Entrepreneurial Courses. These tools help develop compelling marketing materials, build meaningful relationships with investors and secure necessary early-stage funding.

At RESI Boston, June 5-7, tech hub organizations and their startups can utilize:

  • Super Early Bird Registration Rates for full conference or virtual only registrations (startup must be from LSN’s tech hub partners)
  • Complimentary tech hub staff registration
  • 50% off sponsorship opportunities
  • Free second attendee registration for Innovator’s Pitch Challenge (IPC) participants

Life Science Nation will host a free webinar, How Tech Hubs Can Get Involved at RESI Boston, on Wednesday, May 3rd at 12:00PM ET. Register here.

This free webinar is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, regional organizations, and more who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startups who’ve raised less than $2M USD in capital expand their outreach from Regional to Global, build a target list of investors, get involved with the RESI conference series, and more. This webinar will be hosted by Erika Wu, BD Manager of Global Tech Hubs.

FREE_TECH-HUB-WEBINAR_Banner

For more information, please contact Erika Wu, Business Development Manager, Global Tech Hubs of LSN.

RESI-Boston-2023-June-1100px

Connect with 300+ Innovative Life Science Startups at RESI Boston Conference

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Are you representing a service provider, big pharma/medtech, or investor looking to connect with innovative life science startups? Don’t miss the upcoming RESI Boston Conference from June 5-7! With over 300 startups from the therapeutics, medical devices, diagnostics, and digital health/healthcare IT sectors expected to attend, this event provides the perfect opportunity to find your next strategic partner or investment opportunity.

As a registered attendee, you’ll have access to a range of networking opportunities, including 1-1 Partnering Meetings. This efficient system allows you to schedule meetings with startups based on a fit of sector, indication and phase of development.

You can also participate in the Innovator’s Pitch Challenge, where you can hear from some of the most promising startups in the industry as they pitch their ideas to seek licensing opportunities and early-stage funding. This is a great way to get a quick overview of what’s new and exciting in the space.

In addition to these opportunities, RESI Boston also offers sponsored workshops and exhibition spaces, where you can showcase your existing programs, products and services, gaining extra exposure from peers and experts.

Check out RESI Sponsorship Brochure

Don’t miss out on this incredible opportunity to connect with cutting-edge startups and gain valuable industry insights. Register for RESI Boston today and take the first step towards building the future of the life sciences industry.

Check out the RESI Boston June 2023 Featured Startups* below:

*As of April 18, 2023

cs4202023

RESI-Boston-2023-June-1100px

Hot Investor Mandate: Investment Arm of Non-Profit Organization Focuses on Life Science Technologies Targeting Blood Diseases, Infectious Diseases, and More

A venture arm of a non-profit organization with offices in the US closed an initial fund of $50M USD dedicated to early-stage life science ventures from Series A to C. The initial size of investment ranges from $250k-2M and the firm aims to invest in 10 companies in the upcoming year. The firm prefers to invest in US-based companies but is open to global opportunities.

The firm is niched on four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm will consider therapeutics, diagnostics, and medical devices. The firm will consider therapeutics of all modalities from Pre-Clinical to Phase II. Within diagnostics, the firm is opportunistic and looks at technologies in clinical phases or on the market (must include proof of concept). Within medical devices, the firm is open to all technologies, but is more interested in cell therapy-enabling technologies in clinical phases or on the market (must include proof of concept). Focused on the need for blood-related and cellular technologies, the firm is interested in making not only a financial, but humanitarian investments that also tie back to the parent company.

The firm highly values working with a management team that is 100% committed to the project. The firm prefers that the team has an even distribution of members with scientific and commercial expertise. The firm is a strategic co-investor and seeks to work with the respective knowledge experts on the team.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate VC Invests in Early-Stage Life Science Companies, With Strongest Interests in Therapeutics Across All Modalities

A corporate venture arm of a global company has offices in US and Europe. This fund makes equity investments in early stage companies several industries, including healthcare and life sciences. The firm typically leads or co-leads rounds as a member of a syndicate of investors, and is actively seeking new investment opportunities across all funds.

Within life sciences, the firm is looking for early stage companies working primarily within therapeutics, but is open to other sectors and has made investments in medical devices, diagnostics, and digital health. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies. In addition, the firm is seeking innovation for process, research and/or applied solutions.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat. The firm is able to invest globally.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Family Office Invests Globally, With Broad Interests in Promising Life Science Technologies

A family office based in the US represents approximately 2100 doctors, HNW investors, and angel investors. The firm invests in, but is not limited to, biotechnology, medical devices, and pharmaceuticals. Typical allocation size is $100k-250k per investor, participating in both leading investments and co-investing. The firm invests in companies worldwide, with no specific geographic preferences. Recently, the firm had 3 exits in the life science sector.

The firm is opportunistic in terms of sectors of interest. The firm invests in biotechnology, medical devices, pharmaceuticals, and anything relevant to life sciences that seems to be a good opportunity for the firm. The firm is open to all financial rounds and all stages of development as well as orphan diseases and all indications.

The firm does not have any management team requirements, although depending on the case, taking a board seat may be requested.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Company Seeks Global Investment and Strategic Partnering Opportunities With Innovative IVD Products

A large high-tech biological company focuses on rapid diagnostics in China – the company has gone public a few years ago. Apart from their headquarters, the firm has an international presence in Europe, Asia, and North America. The firm is open to different forms of partnership including license-in, joint venture, buyout, and equity investment for early-stage companies.

The firm has a strong interest in IVD sectors for innovative products addressing the unmet needs of healthcare providers.

The firm is open to global opportunities while preferring companies with a Chinese angle.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Global Roadshow Information and Preparation

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN)’s Redefining Early Stage Investment (RESI) conference stands out from the average partnering conference. LSN, from the start, wanted RESI to be a dedicated partnering-centric event.  RESI content is centered on startups and the information they need to succeed in their fundraising endeavors, comprising of investor and licensing partner panels and service provider workshops (see program guides below). There are two main parts to the equation, the 10,000+ early-stage capital investors and licensing partners in the LSN ecosystem, and the 10,000+ startups that are a fit for RESI. This includes those seeking up to 2M in seed funding, $2-10M series A funding, and $10M to 50M series B funding.

The LSN BD staff are not just selling RESI tickets or the LSN investor database but spend a lot of time assessing and making sure that RESI attendees are ready for a global fundraise and understand what it takes to go from the regional stage to the global arena. LSN really cares about the ROI for our clients. It is because of this challenge I have put a bunch of useful links and info that we send along to our RESI and Data leads so that they know what to expect when designing and launching a global roadshow.

At first glance, there are a lot of links/info, but we have found that startups who really want to understand what LSN and RESI are all about typically take the time to explore the subtlety and nuances of going from a regional to a global roadshow mindset.

  • Big4Bio Interview

Listen to the podcast from LSN’s CEO, Dennis Ford, about the journey and challenges life sciences entrepreneurs make when they set out to raise money, what investors care about, and what steps they can take to ensure their success best.

The most successful entrepreneurs are always the best storytellers. Finding a way to formulate your company’s unique story naturally and portraying this through multiple modalities, whether it be a 1-minute elevator pitch or a 12-slide pitch deck, is one of the most effective ways to get potential investors and partners on board with your value proposition. This video will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the players that will emerge along a deal chain, and language tools to refine your hook.

Launching a startup begins with commitment. Commitment to your startup initiative, your executive team, and your partners. Learn how to sustain this commitment by creating a proof of concept or prototype and create market traction initially, considerations to your corporate structure, simplifying finances in the beginning, and what tools to utilize. This video takes you through an honest look at best practices for launching a life science startup.

  • RESI Program Guide

Life Science Nation (LSN) has developed a curriculum on the fundamentals of launching a global partnering campaign. 3 different options are available for early-stage life science startups looking to improve their skill set in fundraising, business development, sales, and marketing.